An interventional study of Collection of blood and urine samples and Clinical examination in Afebrile Seizure (Finding), sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 1 Month to 15 Years. Per ClinicalTrials.gov, last updated 2021-10-28.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Signs and Symptoms with a site in France — 4 open to participants now, 5 under way, 1 of them phase 3. Signs and Symptoms · France.
Among the 14 studies in Signs and Symptoms with a site in France, this one is one of 2 that started in 2017, is one of 5 with no phase, and was the 4th registered.
221 studies on the registry are indexed under Signs and Symptoms; 22 are open to participants now.
Browse Signs and Symptoms studies →4 of the 14 studies in Signs and Symptoms with a site in France are open now. Recruiting first, the newest first:
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
Pfizer · Sites in France, United States, Brazil and 8 more countries
Ages 18+
Institut Rafael · Sites in France
Ages 18+
University Hospital, Caen · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 15 Signs and Symptoms studies recruiting now, 9 (60%) set no upper age limit and 3 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 1 Month to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 78 across 152 interventional studies indexed under Signs and Symptoms.
Median enrollment 89 across the 8 interventional studies, 250 across the 6 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.
University Hospital, Toulouse has 1 study filed under Signs and Symptoms — fewer than ten, so there is no comparison to draw.
1 of the studies in Signs and Symptoms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06317714Institut RafaelLong-term Follow-up and Quality of Life of Patients Treated With Anticancer Drugs | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Signs and Symptoms with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Before the age of 14 years, 1% of the paediatric population will develop a seizure. The only systematically required complementary examination is an electroencephalogram (EEG). Additional biological or radiological examinations depend on the circumstances, the past medical history of the patient and other associated symptoms or clinical signs. A seizure can be the first sign of acute intoxication and represents a severity criterion. Failure to detect the toxic cause of a seizure can lead to a delay in the access or administration of an antidote if applicable. This can lead to target organ toxicity due to the absence of specific treatment. In the current French guidelines for a first seizure, a toxicological analysis is recommended if there is a possibility of exposure to toxic medications or products. However, this screening is often missing, unless a witness suggests that the child may have been exposed to a toxin.The recognition of a paediatric toxidrome is low among paediatricians, paediatric neurologists or emergency physicians. This is due to a lack of knowledge in clinical toxicology and the screening for toxic aetiology is not frequently or irrelevantly prescribed. There is an increasing number of proconvulsive molecules on the market. These molecules are not targeted in classic toxic screening. As result, a toxic cause of a seizure may be missed unless specific screening is performed. For all these reasons, little is known about the prevalence of toxic causes after a first episode of non-febrile seizure and probably under estimated in the paediatric population, especially in young children. New technologies for toxic detection like chromatography combined with mass spectrometry allow wide screening on different matrix. Initially dedicated to forensic analysis, they are more widely accessible for the exploration of the patients. The CASTox study is based on this context.
The first aim will be to evaluate the prevalence of a toxicological cause by a systematic blood and urine screening of children admitted to Toulouse paediatric emergency unit for a first afebrile seizure. Moreover, secondary aim will be to describe the effect of the systematic screening on the management of the children.
Before the age of 14 years, 1% of the paediatric population will develop a seizure. The only systematically required complementary examination is an electroencephalogram (EEG). Additional biological or radiological examinations depend on the circumstances, the past medical history of the patient and other associated symptoms or clinical signs. A seizure can be the first sign of acute intoxication and represents a severity criterion. Failure to detect the toxic cause of a seizure can lead to a delay in the access or administration of an antidote if applicable. This can lead to target organ toxicity due to the absence of specific treatment. In the current French guidelines for a first seizure, a toxicological analysis is recommended if there is a possibility of exposure to toxic medications or products. However, this screening is often missing, unless a witness suggests that the child may have been exposed to a toxin.The recognition of a paediatric toxidrome is low among paediatricians, paediatric neurologists or emergency physicians. Since the end of the 90s, the molecules usually incriminated with seizure onset after intoxication are: with a high risk (polycyclic antidepressant, theophylline, isoniazid); intermediate risk (fluoroquinolones, tramadol, lidocaine, lithium, anticonvulsive medications) and low risk (selective serotonin reuptake inhibitors). Among infants, the molecules are quite different mainly because of the unintentional or malicious aspect of the intoxication and are dominated by sympathomimetic agents, antihistamine drugs, anticholinergic molecules, antidepressants and muscle relaxants. New drugs have been associated with seizures in young intoxicated children like bupropion, tramadol and venlafaxine. These agents are not detected by usual toxic analysis.
For each patient and after getting the signed consent form, a toxicological analysis will be performed on blood and urine samples to extensively screen for proconvulsive molecules (alcohols, polycyclic antidepressants, salicylates, anticonvulsive medications (carbamazepine, phenytoin, valproic acid), drugs (cocaine and its metabolites, amphetamines, methamphetamine (ecstasy), cannabis, buprenorphine, methadone, mephedrone, codeine, pholcodine, hydromorphone), benzodiazepines, caffeine, theophylline, lidocaine, isoniazid, mefenamic acid, tramadol, ephedrine).
This analysis will be performed using classic approach (immunoenzymatic detection) and by chromatography (GC) associated to mass spectrometry (MS) (Laboratory of Toxicology, University Hospital of Toulouse) - The other clinical data, biological results or tests requested by the physician in charge will be reported from the computerized medical file of each patient.
For each patient hospitalized, a follow-up visit will be scheduled during hospitalization in order to report management of the children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand. Intervention : Collection of blood and urine samples, and Clinical examination
Other: Collection of blood and urine samples · Other: Clinical examination
For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
Detection of one or several toxic molecules.
Analyzed by systematic screening of a blood and urine sample.
Time frame: Day 1
The delay of detection of a cause for a first afebrile seizure in paediatric patients.
It is the time between the admission to paediatric emergency unit and the detection of the first afebrile seizure's cause for paediatric patients
Time frame: Day 1
The length of stay in Toulouse paediatric emergency unit or in hospitalization.
Time frame: Day 1
number of tests performed in the search of an aetiology
Time frame: Day 1
The number of tests performed in the search of an aetiology.
Time frame: Day 1
Ran from Dec 2017 to primary completion in Oct 2020, 33 months.
Of 58 non-industry interventional studies with no phase under Signs and Symptoms, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 37. This study's 33 months is above that.
Counting every sponsor, half of 69 studies reached it within 17 months; a quarter within 6 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →